Table of Content



1. Research Scope & Methodology
1.1.Study Objectives
1.2.Scope Of Study
1.3.Methodology
1.4.Assumptions & Limitations

2. Executive Summary
2.1.Market Size & Estimates
2.2.Market Overview

3. Market Dynamics
3.1.Key Drivers
3.1.1. Rise In The Incidence Of Gastrointestinal Ailments
3.1.2. Growing Number Of Drug Developments And Fda Approvals
3.1.3. Surging Occurence Of Irritable Bowel Syndrome
3.1.4. Increasing Geriatric Population
3.2.Key Restraints
3.2.1. High Cost Of Drugs
3.2.2. Lack Of Skilled Professionals In Developing Economies
3.2.3. Limited Treatment Options

4. Key Analytics
4.1.Porter’S Five Forces Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2.Impact Of Covid-19 On Irritable Bowel Syndrome Treatment Market
4.3.Opportunity Matrix
4.4.Vendor Landscape
4.5.Key Investment Insights

5. Market By Type
5.1.Ibs With Diarrhea
5.2.Ibs With Constipation
5.3.Mixed Ibs

6. Market By Product
6.1.Rifaximin
6.2.Eluxadoline
6.3.Linaclotide
6.4.Lubiprostone
6.5.Other Products

7. Market By Distribution Channel
7.1.Drug Stores And Retail Pharmacies
7.2.Hospitals’ Pharmacies
7.3.Online Pharmacies

8. Market By Mechanism Of Action
8.1.5Ht3 Antagonist
8.2.Guanylate Cyclase Receptor-C Agonist
8.3.Chloride Channel Activator
8.4.Other Mechanism Of Actions

9. Market By Dosage
9.1.Solid
9.2.Liquid

10. Geographical Analysis
10.1.Asia Pacific
10.1.1. Market Size & Estimates
10.1.2. Key Growth Enablers
10.1.3. Key Challenges
10.1.4. Key Players
10.1.5. Country Analysis
10.1.5.1. Japan
10.1.5.2. China
10.1.5.3. Australia & New Zealand
10.1.5.4. India
10.1.5.5. South Korea
10.1.5.6. Thailand
10.1.5.7. Indonesia
10.1.5.8. Vietnam
10.1.5.9. Rest Of Asia Pacific

11. Competitive Landscape
11.1.Key Strategic Developments
11.1.1. Merger & Acquisitions
11.1.2. Product Launch & Developments
11.1.3. Partnership, Contract/Agreement & Collaboration
11.1.4. Business Expansion/ Approval/ Announcement
11.2.Company Profile
11.2.1. Abbott Laboratories
11.2.2. Bausch Health Companies Inc
11.2.3. Allergan Plc
11.2.4. Ardelyx Inc
11.2.5. Astellas Pharma Inc
11.2.6. Astrazeneca Plc
11.2.7. Glaxosmithkline Plc
11.2.8. Ironwood Pharmaceuticals Inc
11.2.9. Johnson & Johnson (Mcneil Consumer Healthcare)
11.2.10. Lannett Company Inc
11.2.11. Novartis Ag
11.2.12. Sebela Pharmaceuticals Inc
11.2.13. Synthetic Biologics Inc
11.2.14. Takeda Pharmaceutical Company Ltd



List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Type, In 2020
Figure 6: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Ibs With Diarrhea, 2021-2028 (In $ Million)
Figure 7: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Ibs With Constipation, 2021-2028 (In $ Million)
Figure 8: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Mixed Ibs, 2021-2028 (In $ Million)
Figure 9: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Product, In 2020
Figure 10: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Rifaximin, 2021-2028 (In $ Million)
Figure 11: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Eluxadoline, 2021-2028 (In $ Million)
Figure 12: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Linaclotide, 2021-2028 (In $ Million)
Figure 13: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Lubiprostone, 2021-2028 (In $ Million)
Figure 14: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Other Products, 2021-2028 (In $ Million)
Figure 15: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Distribution Channel, In 2020
Figure 16: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Drug Stores And Retail Pharmacies, 2021-2028 (In $ Million)
Figure 17: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Hospitals’ Pharmacies, 2021-2028 (In $ Million)
Figure 18: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Online Pharmacies, 2021-2028 (In $ Million)
Figure 19: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Mechanism Of Action, In 2020
Figure 20: Asia Pacific Irritable Bowel Syndrome Treatment Market, By 5Ht3 Antagonist, 2021-2028 (In $ Million)
Figure 21: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Guanylate Cyclase Receptor-C Agonist, 2021-2028 (In $ Million)
Figure 22: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Chloride Channel Activator, 2021-2028 (In $ Million)
Figure 23: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Other Mechanism Of Actions, 2021-2028 (In $ Million)
Figure 24: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Dosage, In 2020
Figure 25: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Solid, 2021-2028 (In $ Million)
Figure 26: Asia Pacific Irritable Bowel Syndrome Treatment Market, By Liquid, 2021-2028 (In $ Million)
Figure 27: Asia Pacific Irritable Bowel Syndrome Treatment Market, Country Outlook, 2020 & 2028 (In %)
Figure 28: Japan Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)
Figure 29: China Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)
Figure 30: Australia & New Zealand Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)
Figure 31: India Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)
Figure 32: South Korea Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)
Figure 33: Thailand Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)
Figure 34: Indonesia Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)
Figure 35: Vietnam Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)
Figure 36: Rest Of Asia Pacific Irritable Bowel Syndrome Treatment Market, 2021-2028 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - IRRITABLE BOWEL SYNDROME TREATMENT
TABLE 2: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 10: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 11: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 12: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 13: ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 14: LEADING PLAYERS OPERATING IN ASIA PACIFIC IRRITABLE BOWEL SYNDROME TREATMENT MARKET